François Lucia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1094135/publications.pdf

Version: 2024-02-01

623734 477307 30 901 14 29 citations g-index h-index papers 37 37 37 1243 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	PD-L1 expression in recurrent head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2022, 279, 343-351.	1.6	6
2	Integration of functional imaging in brachytherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 517-525.	1.4	3
3	Predicting response to radiotherapy of head and neck squamous cell carcinoma using radiomics from cone-beam CT images. Acta OncolÁ ³ gica, 2022, 61, 73-80.	1.8	15
4	Unrecognized thoracic radiotherapy toxicity: A review of literature. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 616-621.	1.4	1
5	External Validation of a Radiomics Model for the Prediction of Complete Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. Cancers, 2022, 14, 1079.	3.7	11
6	Radiomics in PET/CT: Current Status and Future Al-Based Evolutions. Seminars in Nuclear Medicine, 2021, 51, 126-133.	4.6	33
7	Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer. Radiotherapy and Oncology, 2021, 155, 144-150.	0.6	33
8	Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3444-3456.	6.4	15
9	[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3432-3443.	6.4	32
10	Dosimetric Validation of a GAN-Based Pseudo-CT Generation for MRI-Only Stereotactic Brain Radiotherapy. Cancers, 2021, 13, 1082.	3.7	15
11	Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer. Journal of Personalized Medicine, 2021, 11, 398.	2.5	12
12	The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2569-2578.	2.5	5
13	N3 (> 6 cm) squamous cell carcinoma of the head and neck: outcomes and predictive factors in 104 patients. Acta Otorhinolaryngologica Italica, 2021, 41, 221-229.	1.5	0
14	Statistical harmonization can improve the development of a multicenter CTâ€based radiomic model predictive of nonresponse to induction chemotherapy in laryngeal cancers. Medical Physics, 2021, 48, 4099-4109.	3.0	15
15	A transfer learning approach to facilitate ComBat-based harmonization of multicentre radiomic features in new datasets. PLoS ONE, 2021, 16, e0253653.	2.5	21
16	Radiation Therapy Planning of Thoracic Tumors: A Review of Challenges Associated With Lung Toxicities and Potential Perspectives of Gallium-68 Lung PET/CT Imaging. Frontiers in Medicine, 2021, 8, 723748.	2.6	12
17	Development and prospective validation of a spatial dose pattern based model predicting acute pulmonary toxicity in patients treated with volumetric arc-therapy for locally advanced lung cancer. Radiotherapy and Oncology, 2021, 164, 43-49.	0.6	10
18	Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases. BMC Cancer, 2020, 20, 991.	2.6	13

#	Article	IF	CITATIONS
19	Use of radiomics in the radiation oncology setting: Where do we stand and what do we need?. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2020, 24, 755-761.	1.4	8
20	Use of Baseline 18F-FDG PET/CT to Identify Initial Sub-Volumes Associated With Local Failure After Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer. Frontiers in Oncology, 2020, 10, 678.	2.8	5
21	Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies. Scientific Reports, 2020, 10, 10248.	3.3	109
22	External Validation of an MRI-Derived Radiomics Model to Predict Biochemical Recurrence after Surgery for High-Risk Prostate Cancer. Cancers, 2020, 12, 814.	3.7	50
23	Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy. Clinical and Translational Radiation Oncology, 2020, 23, 50-59.	1.7	3
24	Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases. Radiotherapy and Oncology, 2019, 130, 132-138.	0.6	36
25	Multicentric validation of radiomics findings: challenges and opportunities. EBioMedicine, 2019, 47, 20-21.	6.1	13
26	MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer. Frontiers in Oncology, 2019, 9, 807.	2.8	35
27	MRI-derived radiomics: methodology and clinical applications in the field of pelvic oncology. British Journal of Radiology, 2019, 92, 20190105.	2.2	38
28	Comparison of Radiomics Models Built Through Machine Learning in a Multicentric Context With Independent Testing: Identical Data, Similar Algorithms, Different Methodologies. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 192-200.	3.7	16
29	External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 864-877.	6.4	138
30	Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 768-786.	6.4	193